Glucose– tag –
-
Kyushu University Breakthrough: Low-Cost, High-Precision Biosensors Drive Next-Gen Personalized Health Monitoring
九州大学 Japan Overview Researchers at Kyushu University's Kameoka Lab are developing a suite of low-cost, high-precision biosensors for continuous, real-time physiological monitoring, designed for seamless integration with the Internet ... -
DexCom Expands Stelo Glucose Biosensor to Non-Insulin-Using Children, Launches Redesigned App in US July 2026
WealthMagik (via Earnings Stability Report) USA Overview DexCom announced FDA approval to expand the Stelo Glucose Biosensor to non-insulin-using children aged 2 and older, aligning with the company's mission to make glucose sensing more... -
Smartwatches Revolutionize Blood Sugar Management: Dexcom G7 and FreeStyle Libre Enhance Apple Watch Integration, Expanding AI-Driven Ecosystem
TechRepublic USA Overview Smartwatches hold the potential to transform glucose tracking, but current advancements rely on the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and regulated healthcare tech... -
Continuous Lactate Monitoring: The Next Breakthrough After CGM, Driven by Wearable Sensors and AI
After CGM (Diabetes in Control) USA Overview While Continuous Glucose Monitoring (CGM) revolutionized diabetes management, Continuous Lactate Monitoring (CLM) is now discussed as the next significant advance in metabolic monitoring. Lact... -
GoodRx Compares Leading CGMs: Dexcom G7 10-Day Sensor Emerges as Sole FDA-Approved Device for Children Ages 2+
GoodRx USA Overview According to a GoodRx comparison report, the Dexcom G7 10-day sensor is FDA-approved for adults and children aged 2 and older, while the Dexcom G7 15-day sensor and Eversense 365 are approved exclusively for adults ag... -
AI, Digital Health, & Remote Monitoring Revolutionize Obesity Care: Real-time Intervention via Wearables & Mobile Apps
AI in Digital Health & Remote Monitoring India Overview Artificial Intelligence (AI), digital health platforms, and remote patient monitoring systems are rapidly transforming the healthcare industry's approach to obesity and metabolic di... -
The Rise of Finger-Prick-Free Glucose Monitoring: Dexcom Stelo, Abbott Lingo, and the CGM Revolution in Metabolic Health
Mattioli 1885 イタリア Overview The U.S. FDA has approved a new generation of finger-prick-free continuous glucose monitors (CGMs) that measure interstitial fluid glucose and transmit real-time data to smartphones, largely eliminating da... -
Trinity Biotech’s AI-Powered CGM+ Biosensor Slashes False Low Glucose Alarms by Over 95%
Trinity Biotech plc (NASDAQ: TRIB) アイルランド Overview Trinity Biotech plc has announced groundbreaking clinical trial results for its next-generation CGM+ wearable biosensor platform. This innovative system leverages AI-driven analyti... -
FDA Clears Dexcom Stelo as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children (Ages 2+)
HCPLive USA Overview The FDA has approved Dexcom's Stelo Glucose Biosensor System for over-the-counter (OTC) use in children aged 2 years and older who do not use insulin. This marks Stelo as the first OTC continuous glucose monitoring (... -
Dexcom Advances ‘Glucose Biosensing for All’ Vision with Pediatric Clearance for Stelo Biosensor and Relaunch of Redesigned App
Business Wire USA Overview Dexcom announced key milestones at Aspen Ideas: Health, including pediatric clearance for its Stelo Glucose Biosensor and the July launch of a redesigned Stelo app for Apple and Android users. These advancement...
